Written by Klarity Editorial Team
Published: Nov 7, 2025

Key takeaway: Stopping an SSRI too quickly can cause discontinuation syndrome, with symptoms including dizziness, brain zaps, nausea, and mood changes. In 2026, updated APA guidelines and growing research on hyperbolic tapering have changed how clinicians approach SSRI discontinuation. Always work with a licensed provider when tapering or stopping an antidepressant.
Need help tapering your SSRI safely? Klarity connects you with licensed providers for same-day online appointments — many insurance plans may cover your visit. See if you may qualify →
Switching antidepressants or discontinuing medications like Lexapro can be a challenging journey, often complicated by withdrawal symptoms that many patients aren’t adequately prepared for. If you’ve experienced agitation, crying spells, irritability, or insomnia during an antidepressant taper, you’re not alone. Up to 56% of patients who discontinue antidepressants report experiencing withdrawal symptoms, yet many feel their concerns are dismissed by healthcare providers. This comprehensive guide will help you understand SSRI discontinuation syndrome, recognize the importance of proper tapering protocols, and advocate for yourself during medication transitions.
Selective Serotonin Reuptake Inhibitors (SSRIs) like Lexapro (escitalopram) and Zoloft (sertraline) work by increasing serotonin levels in the brain. When these medications are reduced too quickly, your brain doesn’t have time to adjust to the changing serotonin levels, resulting in what’s clinically termed ‘SSRI discontinuation syndrome.’
Withdrawal symptoms can vary in severity and may include:
A fast taper—such as going from 10mg to 0mg of Lexapro within 5 days—can trigger severe withdrawal symptoms. Research suggests that a gradual taper over weeks or even months is significantly more successful and less distressing for patients.
While individual needs vary, a general guideline for Lexapro tapering might look like:
Cross-tapering involves gradually decreasing one medication while simultaneously introducing another. Direct switching—stopping one medication completely before starting another—is generally not recommended for SSRIs like Lexapro and Zoloft due to withdrawal risks.
The approach to SSRI discontinuation has evolved significantly by 2026. The American Psychiatric Association’s updated guidance, informed by a growing body of research on antidepressant discontinuation syndrome, now recommends that clinicians individualize tapering schedules based on the duration of antidepressant use, the specific drug, and the patient’s history of discontinuation symptoms.
A particularly important 2026 development is the increased clinical adoption of hyperbolic tapering protocols. Research has demonstrated that serotonin receptor occupancy does not decrease linearly as dose is reduced. Instead, the final dose reductions produce disproportionately large changes in receptor occupancy, which is why patients who taper too quickly at the end of a schedule often experience the most severe discontinuation symptoms. Hyperbolic tapering addresses this by making the final dose reductions progressively smaller, using liquid formulations or specialty compounded preparations to achieve precise low doses.
In 2026, more compounding pharmacies offer low-dose liquid SSRI preparations specifically to support hyperbolic tapering, and several major health systems have added hyperbolic tapering protocols to their clinical pathways. Patients experiencing significant discontinuation symptoms should discuss switching to a longer-acting SSRI such as fluoxetine as a bridging strategy, which may reduce symptom severity during the final taper.
SSRI discontinuation syndrome is a cluster of symptoms that can occur when an SSRI is stopped or reduced too quickly. Symptoms include dizziness, brain zaps, nausea, flu-like feelings, mood changes, and sleep disturbances. It is not a sign of addiction; it reflects the brain’s adjustment to reduced serotonin signaling.
Tapering duration varies widely depending on how long you have been on the medication, which SSRI you are taking, and your personal history. Some patients taper over a few weeks; others with a longer history of use may benefit from a taper lasting several months, particularly when using hyperbolic protocols.
Hyperbolic tapering is an approach to SSRI discontinuation that makes progressively smaller dose reductions as you approach zero, based on the pharmacology of serotonin receptor occupancy. It is supported by growing research and is increasingly recommended in clinical guidelines for patients who experience difficulty with standard tapering.
In some cases, switching to a longer-acting SSRI like fluoxetine before tapering can reduce discontinuation symptoms. This is a clinical decision that should be made with your provider based on your specific situation.
Yes. Klarity’s licensed providers offer same-day online appointments for medication management, including SSRI tapering planning. See if you may qualify for covered care.
Find the right provider for your needs — select your state to find expert care near you.